Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade

22 Mar 2023

Abstract excerpt

Whereas the contribution of tumor microenvironment to the profound immune suppression of glioblastoma (GBM) is clear, tumor-cell intrinsic mechanisms that regulate resistance to CD8 T cell mediated killing are less understood. Kinases are potentially druggable targets that drive tumor progression and might influence immune response. Here, we perform an in vivo CRISPR screen to identify glioma intrinsic kinases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Glioma Diagnosis and Treatment
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36949040
DOI: 10.1038/s41467-023-36878-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockadePMID 36949040Read ↗

MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, microglia phenotype, and immune checkpoint blockade efficacySemantic proximity Read ↗

Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors.Semantic proximity Read ↗

Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses.Semantic proximity Read ↗

High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for GliomaSemantic proximity Read ↗

Mapping kinase-dependent tumor immune adaptation with multiplexed single-cell CRISPR screensSemantic proximity Read ↗

CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.Semantic proximity Read ↗

Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastomaSemantic proximity Read ↗

EGFL7 promotes immune evasion in glioblastoma by interaction with integrin β <sub>2</sub>Semantic proximity Read ↗

Dual checkpoint blockade of glioblastoma with Anti-PD-1 and Anti-LAG-3 promotes expansion of tumor-reactive T cell clones along a unique pathway of differentiationSemantic proximity Read ↗

Natural Killer Cells Suppress T Cell-Associated Tumor Immune EvasionSemantic proximity Read ↗

CD8+ T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomasSemantic proximity Read ↗

Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.